Recombinant Human NFKBID, N-His

Title: Introduction to Recombinant Human NFKBID: Structure, Activity and Applications

Recombinant Human NFKBID, also known as nuclear factor-kappa B inhibitor delta (NFKBID), is a protein that plays a crucial role in regulating the activity of the transcription factor NF-kappa B. This protein is encoded by the NFKBID gene and is a member of the I-kappa-B family of proteins, which are known to inhibit the activity of NF-kappa B.

Structure of Recombinant Human NFKBID:

The recombinant form of human NFKBID is a 37 kDa protein with a total of 327 amino acids. It consists of an N-terminal domain, a central ankyrin repeat domain, and a C-terminal domain. The N-terminal domain is responsible for binding to NF-kappa B, while the ankyrin repeat domain is involved in protein-protein interactions. The C-terminal domain contains a PEST motif, which is important for regulating the stability of the protein.

Activity of Recombinant Human NFKBID:

The primary function of recombinant human NFKBID is to inhibit the activity of NF-kappa B, a transcription factor that plays a critical role in the regulation of immune responses, inflammation, and cell survival. NFKBID achieves this by binding to the Rel homology domain of NF-kappa B, thereby preventing its translocation into the nucleus and subsequent activation of target genes. This inhibition of NF-kappa B activity by NFKBID is crucial for maintaining immune homeostasis and preventing excessive inflammation.

Applications of Recombinant Human NFKBID:

1. Recombinant Human NFKBID as a research tool:

Recombinant human NFKBID has been widely used as a research tool to study the role of NF-kappa B in various cellular processes. Its ability to specifically inhibit NF-kappa B activity has allowed researchers to elucidate the downstream effects of NF-kappa B signaling in different cell types and disease models.

2. Recombinant Human NFKBID in drug discovery:

Given the importance of NF-kappa B in various diseases, NFKBID has been explored as a potential therapeutic target. Recombinant human NFKBID has been used in high-throughput screening assays to identify small molecule inhibitors of NF-kappa B, which could potentially be developed into drugs for the treatment of inflammatory and autoimmune diseases.

3. Recombinant Human NFKBID in cancer research:

NF-kappa B is known to play a role in cancer development and progression. As a specific inhibitor of NF-kappa B, recombinant human NFKBID has been studied in various cancer models to understand its potential as a therapeutic agent. It has been shown to inhibit the growth of cancer cells and sensitize them to chemotherapy and radiotherapy, making it a promising candidate for cancer therapy.

4. Recombinant Human NFKBID in vaccine development:

NF-kappa B is also involved in the regulation of immune responses to pathogens. Recombinant human NFKBID has been used in vaccine development to enhance the immune response against specific antigens. By inhibiting NF-kappa B, NFKBID can promote the activation of antigen-presenting cells and enhance the production of antibodies against the target antigen.

In conclusion, recombinant human NFKBID is a crucial protein that plays a significant role in regulating NF-kappa B activity. Its structure, activity, and applications make it a valuable tool in various fields of research, including drug discovery, cancer research, and vaccine development. Further studies on this protein may lead to the development of novel therapeutics for the treatment of various diseases.

ProteoGenix catalogue number ARO-P13230. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 28.18 kDa; Fragment: Asp46-Val285; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet